Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Mallinckrodt Plc (MNKKQ)

Mallinckrodt Plc (MNKKQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Mallinckrodt plc to Report Earnings Results for Second Quarter 2025 PR Newswire - Tue Jul 22, 2025

DUBLIN , July 22, 2025 /PRNewswire/ -- Mallinckrodt plc , a global specialty pharmaceutical company, today announced that it will report its second quarter 2025 financial...

MNKKQ : 0.0200 (+10.50%)
MNK : 0.3402 (-14.97%)
Mallinckrodt Announces Resubmission of Terlipressin to the FDA for the Treatment of Hepatorenal Syndrome PR Newswire - Mon Jun 13, 2022

/PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced the resubmission of the Company's New Drug Application...

MNKKQ : 0.0200 (+10.50%)
Mallinckrodt Announces Anticipated Chapter 11 Emergence and Provides Update on Trading of New Ordinary Shares PR Newswire - Mon Jun 13, 2022

/PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that it expects to complete its reorganization process,...

MNKKQ : 0.0200 (+10.50%)
Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501 Business Wire - Wed Mar 23, 2022

Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant...

MNKKQ : 0.0200 (+10.50%)
SLN : 5.04 (-9.35%)

Barchart Exclusives

After Rigetti Announced a Quantum Computing Delay, How Should You Play RGTI Stock in January 2026? Barchart - 1 hour ago
Rigetti’s delay of its flagship 108-qubit Cepheus system rattled investor confidence. Is RGTI still worth buying this month? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot